EP3952840A4 - Compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs - Google Patents

Compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs Download PDF

Info

Publication number
EP3952840A4
EP3952840A4 EP19924315.5A EP19924315A EP3952840A4 EP 3952840 A4 EP3952840 A4 EP 3952840A4 EP 19924315 A EP19924315 A EP 19924315A EP 3952840 A4 EP3952840 A4 EP 3952840A4
Authority
EP
European Patent Office
Prior art keywords
behavioral
methods
pharmaceutical compositions
cognitive disorders
treating mental
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19924315.5A
Other languages
German (de)
English (en)
Other versions
EP3952840A1 (fr
Inventor
Jianmin Wang
Geping Cui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Pharma Tech Inc
Original Assignee
La Pharma Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Pharma Tech Inc filed Critical La Pharma Tech Inc
Publication of EP3952840A1 publication Critical patent/EP3952840A1/fr
Publication of EP3952840A4 publication Critical patent/EP3952840A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP19924315.5A 2019-04-12 2019-04-12 Compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs Pending EP3952840A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/027293 WO2020209872A1 (fr) 2019-04-12 2019-04-12 Compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs

Publications (2)

Publication Number Publication Date
EP3952840A1 EP3952840A1 (fr) 2022-02-16
EP3952840A4 true EP3952840A4 (fr) 2022-11-23

Family

ID=72751206

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19924315.5A Pending EP3952840A4 (fr) 2019-04-12 2019-04-12 Compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs

Country Status (6)

Country Link
EP (1) EP3952840A4 (fr)
JP (1) JP7365426B2 (fr)
CN (1) CN113939276A (fr)
AU (1) AU2019445048A1 (fr)
CA (1) CA3136633A1 (fr)
WO (1) WO2020209872A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US10898493B2 (en) 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US10966989B2 (en) 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
CA3137393A1 (fr) * 2019-04-30 2020-11-05 Jianmin Wang Procede de traitement de troubles mentaux, comportementaux et cognitifs
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007006233A (es) * 2004-11-24 2007-11-23 Medpointe Healthcare Inc Composiciones que comprenden azelastina y metodos de uso de la misma.
WO2014018563A2 (fr) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Procédés pour le traitement du cancer
US20190269627A1 (en) * 2016-10-28 2019-09-05 Chase Pharmaceuticals Corporation Memantine combinations and use
JP7198575B2 (ja) * 2017-07-11 2023-01-04 キョーリンリメディオ株式会社 メマンチン塩酸塩含有口腔内崩壊錠

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AIKO HATAKEYAMA ET AL: "AZELASTINE HYDROCHLORIDE ON BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS AND ACTIVITIES OF DAILY LIVING IN DEMENTIA PATIENTS", GERIATR. GERONTOL. INT,, vol. 8, 1 January 2008 (2008-01-01), pages 59 - 61, XP002798078 *
TARIOT PIERRE N ET AL: "MEMANTINE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER DISEASE ALREADY RECEIVING DONEPEZIL. A RANDOMIZED CONTROLLED TRIAL", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, AMERICAN MEDICAL ASSOCIATION, US, vol. 291, no. 3, 21 January 2004 (2004-01-21), pages 317 - 324, XP009075923, ISSN: 0098-7484, DOI: 10.1001/JAMA.291.3.317 *

Also Published As

Publication number Publication date
AU2019445048A1 (en) 2021-12-02
JP7365426B2 (ja) 2023-10-19
CN113939276A (zh) 2022-01-14
JP2022535644A (ja) 2022-08-10
WO2020209872A1 (fr) 2020-10-15
CA3136633A1 (fr) 2020-10-15
EP3952840A1 (fr) 2022-02-16

Similar Documents

Publication Publication Date Title
EP3952840A4 (fr) Compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs
EP3973586A4 (fr) Nouvelles compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs
EP3351616A4 (fr) Nouveau lactobacillus et composition pour prévenir, atténuer ou traiter des maladies cérébrales dégénératives ou des troubles de la fonction cognitive
EP3931189A4 (fr) Azépino-indoles et autres hétérocycles pour traiter des troubles du cerveau
EP3746135A4 (fr) Procédés et composés pour traiter des troubles
EP3675859A4 (fr) Composés, compositions et méthodes pour le traitement d'une maladie
EP3934652A4 (fr) Composés, compositions et procédés pour le traitement d'une maladie
EP3962488A4 (fr) Procédé de traitement de troubles mentaux, comportementaux et cognitifs
EP3906043A4 (fr) Procédés et compositions pour le traitement de la maladie de fabry
EP3681477A4 (fr) Méthode et composition améliorée pour le traitement d'états pathologiques, de maladies ou de troubles sensibles aux triterpènes
EP3810611A4 (fr) Dérivés de benzodiazépine, compositions, et méthodes de traitement de déficience cognitive
EP3507371A4 (fr) Méthodes et compositions pour traiter des maladies et des troubles du système nerveux
EP3858353A4 (fr) Composition pharmaceutique pour prévenir et traiter la nitm et utilisation pharmaceutique associée
EP3492096A4 (fr) Composition pharmaceutique pour le traitement de maladies oculaires, contenant une protéine cas9 et un arn guide
EP3818085A4 (fr) Compositions et leurs utilisations pour traiter une maladie ou un état pathologique
EP3934646A4 (fr) Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires
EP4034109A4 (fr) Méthode et composition pour le traitement d'une maladie
EP3636281A4 (fr) Méthode de traitement de la dépression, et composition pharmaceutique
EP3570670A4 (fr) Compositions et procédés de traitement de maladies et de troubles du stockage lysosomial
EP3943107A4 (fr) Composition pour prévenir ou traiter une maladie du cerveau et du système nerveux
EP3600324A4 (fr) Composés et compositions pour le traitement de troubles oculaires
EP3558281A4 (fr) Traitement de troubles mentaux, du mouvement et du comportement
EP4043012A4 (fr) Médicament pour le traitement de maladies artérielles et son utilisation
EP3946433A4 (fr) Compositions, dispositifs et méthodes de traitement de la maladie de fabry
EP3979985A4 (fr) Compositions et méthodes pour traiter des troubles du système nerveux central

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211111

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20221024

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20221018BHEP

Ipc: A61K 47/00 20060101ALI20221018BHEP

Ipc: A61K 31/495 20060101ALI20221018BHEP

Ipc: A61K 31/55 20060101ALI20221018BHEP

Ipc: A61K 31/13 20060101ALI20221018BHEP

Ipc: A61K 9/48 20060101ALI20221018BHEP

Ipc: A61K 9/20 20060101ALI20221018BHEP

Ipc: A61K 9/14 20060101ALI20221018BHEP

Ipc: A61K 9/10 20060101ALI20221018BHEP

Ipc: A61K 9/08 20060101AFI20221018BHEP